GlassScriptPhysician profile
Joseph Tibaldi
NPI 1972588564
$120,896.36
in general payments reported to CMS, 2019-2025
9 companies · $30.92 in 2025
The $30.92 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79K · 2020: $22K · 2021: $17K · 2022: $3,349 · 2023: $81.72 · 2024: $93.67 · 2025: $30.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $206.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $101,678.11 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $16,863.14 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $2,061.09 | 2019 | |
| Medtronic Minimed, INC. | $125.00 | 2019 | |
| Lilly USA, LLC | $58.05 | 2024-2025 | Mounjaro, Zepbound |
| Amgen INC. | $32.90 | 2023-2024 | Prolia, Evenity |
| Tandem Diabetes Care, INC. | $32.01 | 2019 | |
| Abbott Laboratories | $24.14 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Tibaldi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.